In re Zymergen, Inc. IPO Securities Litigation Settlement (Wang v. Zymergen)
What this is about
Investors alleged Zymergen made false and misleading statements and omissions in connection with its initial public offering under Sections 11 and 15 of the Securities Act of 1933, damaging purchasers of Zymergen common stock.
The background
Wang v. Zymergen, Inc. is a securities class action asserting claims under Sections 11 and 15 of the Securities Act of 1933 based on allegedly false and misleading statements and omissions to investors in Zymergen's IPO. On June 22, 2026 the Court granted preliminary approval of the proposed $125,000,000 settlement. Proofs of Claim must be submitted online or postmarked by October 11, 2026; the settlement hearing is scheduled for October 13, 2026. Claims administrator is Verita Global (mail: Zymergen Securities Litigation c/o Verita Global, P.O. Box 301135, Los Angeles, CA 90030-1135).com (.
Worth knowing
Wang v. Zymergen, Inc. is a securities class action asserting claims under Sections 11 and 15 of the Securities Act of 1933 based on allegedly false and misleading statements and omissions to investors in Zymergen's IPO. On June 22, 2026 the Court granted preliminary approval of the proposed $125,000,000 settlement. Proofs of Claim must be submitted online or postmarked by October 11, 2026; the settlement hearing is scheduled for October 13, 2026. Claims administrator is Verita Global (mail: Zymergen Securities Litigation c/o Verita Global, P.O. Box 301135, Los Angeles, CA 90030-1135).com (.
File your claim on the official site →Common questions
How much can I get from the In re Zymergen, Inc. IPO Securities Litigation Settlement (Wang v. Zymergen)?
Pro rata share of a $125,000,000 settlement fund (approximately $6.21 per eligible share under the Plan of Allocation, before fees and costs).
What happened in the In re Zymergen, Inc. IPO Securities Litigation Settlement (Wang v. Zymergen) case?
Investors alleged Zymergen made false and misleading statements and omissions in connection with its initial public offering under Sections 11 and 15 of the Securities Act of 1933, damaging purchasers of Zymergen common stock.
How do I actually file a claim?
Use the official claim link on this page — it goes directly to the real claims administrator or court-approved site. We never collect claim submissions ourselves and never charge a fee to help you file.
Where does this information come from?
This entry was last verified on September 04, 2026 against its primary source (the official claims administrator, court record, or government page) — linked below. We re-check it, not just copy it once.
Want to know when settlements like this open up?
We check for new Financial Services & Banking claims daily. Tell us your email and we'll send a weekly rundown of what's new — no spam, unsubscribe anytime.